PATH | VRL
Menu

Find resources

Total results with these characteristics: 66

Disease: Respiratory syncytial virus (RSV)

Page 2 of 4
Global, Regional, and National Disease Burden Estimates of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children in 2015: A Systematic Review and Modelling Study

This article, published in The Lancet, reports the results of a study estimating the global burden of respiratory syncytial virus (RSV) in young children, incorporating substantial new data from developing countries. The authors estimated that in …

Author: Shi T, McAllister DA, O’Brien KL, et al.

Publication date: 2017

Immunopathology of RSV Infection: Prospects for Developing Vaccines Without This Complication

This article, published in Reviews in Medical Virology, outlines the different challenges to developing a vaccine against respiratory syncytial virus (RSV). The authors note that maternal vaccination may be an optimal strategy to protect very young …

Author: van Drunen Littel-van den Hurk S, Mapletoft JW, Arsic N, Kovacs-Nolan J

Publication date: 2007

Impact of Placental Malaria and Hypergammaglobulinemia on Transplacental Transfer of Respiratory Syncytial Virus Antibody in Papua New Guinea

As maternal immunization becomes an increasingly important strategy for protection of very young infants, identification of factors that could impact vaccine effectiveness by modifying the efficiency of transplacental antibody transport will be …

Author: Atwell JE, Thumar B, Robinson LJ, et al.

Publication date: 2016

Jordan Report: Accelerated Development of Vaccines 2012

This comprehensive report includes expert articles on a variety of vaccine-related topics and updates on vaccine research for specific infectious diseases, such as influenza, malaria, respiratory syncytial virus, and rotavirus.

Author: US National Institute of Allergy and Infectious Diseases

Publication date: 2012

Landscape Analysis: Trends in Vaccine Availability and Novel Vaccine Delivery Technologies: 2008–2025

This landscape analysis identifies trends in the availability of vaccines and novel vaccine delivery technologies that are and will be of relevance to low- and middle-income countries from the present through 2025.

Author: PATH, World Health Organization

Publication date: 2008

Maternal Immunization Against Viral Disease

This article, published in Vaccine, discusses the advantages and disadvantages of maternal immunization to augment the protective effect of maternal antibody against many viral diseases in the young infant. The authors also present more specific …

Author: Englund J, Glezen WP, Piedra PA

Publication date: 1998

Maternal Immunization: Country Priorities and Market Requirements

Maternal immunization is an approach of vaccinating during pregnancy to enhance immunity for both mother and baby. This report provides insight into country priorities for maternal immunization and characterizes the market for adult immunizations in …

Author: PATH

Publication date: 2015

Maternal Immunization Safety Monitoring in Low- and Middle-Income Countries: A Roadmap for Program Development

Maternal immunization holds the promise of further reducing morbidity and mortality among pregnant women and infants, particularly in low- and middle-income countries (LMICs) where there is the greatest burden of vaccine-preventable disease. This …

Author: Global Alliance to Prevent Prematurity and Stillbirth (GAPPS)

Publication date: 2017

Maternal Transfer of RSV Immunity in Cotton Rats Vaccinated During Pregnancy

Maternal antibodies against respiratory syncytial virus (RSV) can protect infants from the disease, but the protection is short-lived and the methods for extending and augmenting protection are not known. This article, published in Vaccine, reports …

Author: Blanco JCG, Pletneva LM, Oue RO, Patel MC, Boukhvalova MS

Publication date: 2015

Moving the Needle

This quarterly e-newsletter provides updates from PATH’s Center for Vaccine Innovation and Access on its vaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of …

Author: PATH

A Multi-Laboratory Study of Diverse RSV Neutralization Assays Indicates Feasibility for Harmonization With an International Standard

This article, published in Vaccine, assesses the current level of agreement between 12 virus neutralization assay formats used in the evaluation of vaccine candidates for respiratory syncytial virus (RSV), a leading cause of lower respiratory tract …

Author: Hosken N, Plikaytis B, Trujillo C, Mahmood K, Higgins D, the Participating Laboratories Working Group

Publication date: 2017

Neutralizing Antibodies Against the Preactive Form of Respiratory Syncytial Virus Fusion Protein Offer Unique Possibilities for Clinical Intervention

The only specific treatment available today against human respiratory syncytial virus (hRSV) is a humanized monoclonal antibody (Palivizumab) directed against the F glycoprotein, administered prophylactically to children at very high risk of severe …

Author: Magro M, Mas V, Chappell K, et al.

Publication date: 2012

Neutralizing Epitopes on the Respiratory Syncytial Virus Fusion Glycoprotein

The respiratory syncytial virus viral fusion glycoprotein (RSV F) is the major target of neutralizing antibodies, making it a target for vaccine development. This article, published in Current Opinion in Virology, summarizes recently determined …

Author: McLellan JS

Publication date: 2015

Path to Impact: A Report From the Bill and Melinda Gates Foundation Convening on Maternal Immunization in Resource-Limited Settings; Berlin – January 29-30, 2015

This article, published in Vaccine, presents the outcomes of a convening of global stakeholders in vaccine development, policy, and delivery, as well as the maternal, newborn, and child health community, on the potential of maternal immunization to …

Author: Sobanjo-ter Meulen A, Abramson J, Mason E, et al.

Publication date: 2015

Paving the Way for Respiratory Syncytial Virus Prevention: Vaccine Development Against a Widespread Cause of Respiratory Illness in Infants and Young Children

This fact sheet highlights PATH's work to develop a vaccine against respiratory syncytial virus (RSV) with the potential to help control RSV in the developing world through prevention.

Author: PATH

Publication date: 2013

Pneumonia

This fact sheet provides an overview of the causes, means of transmission, symptoms, risk factors, treatment, prevention, and economic costs of pneumonia. Also outlined is the World Health Organization's action plan to prevent and treat pneumonia, …

Author: World Health Organization

Publication date: 2012

Preparation of a Respiratory Syncytial Virus Human Reference Serum for Use in the Quantitation of Neutralization Antibody

Currently, immune responses to experimental respiratory syncytial virus (RSV) vaccines are usually evaluated by two different assays, however both types are generally performed differently at different laboratories. This article, published in …

Author: Yang DP, Zielinska E, Quiroz J, Madore D, Rappaport R

Publication date: 2007

Prevention of Serious Respiratory Syncytial Virus-Related Illness. I: Disease Pathogenesis and Early Attempts at Prevention

This article, published in Advances in Therapy, provides an overview of the pathogenesis of respiratory syncytial virus (RSV), the historical challenges facing RSV vaccine development, and current technologies being explored to prevent RSV disease. …

Author: Groothuis JR, Hoopes JM, Hemming VG

Publication date: 2011

Prevention of Serious Respiratory Syncytial Virus-Related Illness. II: Immunoprophylaxis

This article, published in Advances in Therapy, reviews the development and use of palivizumab, the only drug approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease. Palivizumab is a monoclonal antibody that …

Author: Groothuis JR, Hoopes JM, Hemming VG

Publication date: 2011

Protecting Aluminum-Adjuvanted Vaccines From Freeze Damage

This fact sheet describes how PATH developed a low-cost and straightforward technology for protecting aluminum-adjuvanted liquid vaccines from the irreversible damage that results from freezing. Many current vaccines of importance to global health …

Author: PATH

Publication date: 2012

Page 2 of 4